摘要
目的分析排毒生血汤联合促红细胞生成素治疗肾性贫血的疗效。方法选择2018年1月至2020年1月收治的128例肾性贫血患者,随机分为对照组和观察组,每组64例。2组在西医常规治疗的基础上,对照组予以促红细胞生成素治疗,观察组予以排毒生血汤联合促红细胞生成素治疗;持续治疗8周,比较2组治疗前后的血红蛋白(Hb)、红细胞压积(HCT)、红细胞(RBC)水平、铁代谢指标[血清铁(SI)、可溶性转铁蛋白受体(sTFR)、转铁蛋白饱和度(TSAT)、总铁结合力(TIBC)]、肝肾功能指标,综合评价疗效和不良反应发生情况。结果2组治疗后Hb、HCT和RBC水平均较治疗前升高,且观察组优于对照组,差异均有统计学意义(P<0.05);2组治疗后SI、sTFR、TSAT和TIBC水平均较治疗前改善,且观察组治疗后sTFR水平低于对照组,差异有统计学意义(P<0.05);2组治疗后肝肾功能指标均未较治疗前明显变化(P<0.05);观察组临床显效率、总有效率均高于对照组,差异均有统计学意义(P<0.05);观察组不良反应发生率为6.25%低于对照组的18.75%,差异有统计学意义(P<0.05)。结论排毒生血汤联合促红细胞生成素治疗能协同改善肾性贫血状况和铁代谢,以增加临床获益,安全性尚可,值得临床重视应用。
Objective To analyze the efficacy of Paidu Shengxue Decoction combined with erythropoietin(EPO)for renal anemia(RA).Methods The RA patients(n=128)admitted to our hospital from January 2018 to January 2020 were randomly assigned into the observation group(n=64)and the control group(n=64).Apart from routine Western medicine,the control group received EPO,and the observation group received Paidu Shengxue Decoction based on control group.A 8-week treatment was performed to compare hemoglobin(Hb),hematocrit(HCT),red blood cell(RBC),iron parameters(serum iron,soluble transferrin receptor,transferrin saturation,total iron binding capacity),liver and kidney function indexes;the curative effect and adverse reaction were assessed.Results After treatment,Hb,HCT and RBC in groups were increased,the observation group was significantly better than the control group(P<0.05);SI,sTFR,TSAT,TIBC in groups were improved,sTFR was notably decreased in the observation group as compared to the control group(P<0.05).The liver and kidney function indexes in groups did not change significantly after treatment(P<0.05).The clinical effective rate and the overall effective rate in the observation group were obviously increased in comparison with the control group(P<0.05).The incidence of adverse reactions was significantly lower in the observation group than the control group and with statistically difference(6.25%vs 18.75%,P<0.05,respectively).Conclusion Paidu Shengxue Decoction combined with EPO is capable of improving RA and iron metabolism,further increasing clinical benefits,with certain safety and worthy of clinical application.
作者
魏善斋
孙杰
许康春
李一北
张以来
WEI Shanzhai;SUN Jie;XU Kangchun(Shuyang Hospital of Traditional Chinese Medicine,Jiangsu,Shuyang 223600,China)
出处
《河北医药》
CAS
2022年第22期3427-3429,3433,共4页
Hebei Medical Journal
基金
宿迁市科技局项目(编号:Z2020062)。
作者简介
通讯作者:张以来,E-mail:weishanzhai88451@163.com。
